Anesthetic agents can induce a paradox activation and sensitization of nociceptive sensory neurons and, thus, potentially facilitate pain processing. Here we identify distinct molecular mechanisms that mediate an activation of sensory neurons by 2,6-diisopropylphenol (propofol), a commonly used intravenous anesthetic known to elicit intense pain upon injection. Clinically relevant concentrations of propofol activated the recombinant transient receptor potential (TRP) receptors TRPA1 and TRPV1 heterologously expressed in HEK293t cells. In dorsal root ganglion (DRG) neurons, propofol-induced activation correlated better to expression of TRPA1 than of TRPV1. However, pretreatment with the protein kinase C activator 4-phorbol 12-myristate 13-acetate (PMA) resulted in a significantly sensitized propofol-induced activation of TRPV1 in DRG neurons as well as in HEK293t cells. Pharmacological and genetic silencing of both TRPA1 and TRPV1 only partially abrogated propofol-induced responses in DRG neurons. The remaining propofol-induced activation was abolished by the selective ␥-aminobutyric acid, type A (GABA A ) receptor antagonist picrotoxin. Propofol but not GABA evokes a release of calcitonin generelated peptide, a key component of neurogenic inflammation, from isolated peripheral nerves of wild-type but not TRPV1 and TRPA1-deficient mice. Moreover, propofol but not GABA induced an intense pain upon intracutaneous injection. As both the release of calcitonin gene-related peptide and injection pain by propofol seem to be independent of GABA A receptors, our data identify TRPV1 and TRPA1 as key molecules for propofol-induced excitation of sensory neurons. This study warrants further investigations into the role of anesthetics to induce nociceptor sensitization and to foster postoperative pain.The intravenous general anesthetic propofol 3 (2,6-diisopropylphenol) has become one of the most widely used anesthetics.Due to a short context-sensitive half-time, propofol is used for sedations as well as for total intravenous anesthesia during surgery. A drawback of propofol, however, is its high potential to induce intense burning pain upon injection. Depending on the concentration (0.5-2%), the galenic formulation, and co-medication, 24 -90% of all patients receiving propofol experience injection pain (1). It was hypothesized that propofol might indirectly or directly interact with sensory nerve fibers located in the venous adventitia (2-4). A recent study claims that the irritant receptor TRPA1, which is expressed in nociceptive sensory neurons, is the predominant molecular entity mediating activation of peripheral nerve endings by general anesthetics (5). Also, TRPA1 was found to mediate propofol-induced pain behavior induced by intranasal propofol and flexor reflex response upon intra-arterial propofol (5). TRPA1 is an excitatory cation channel that is activated by pungent or irritating substances such as acrolein, mustard oil, and formalin (6). TRPA1 has also been demonstrated to be involved in the development of increa...